/Technology%20abstract%20by%20TU%20IS%20via%20iStock.jpg)
As quantum computing is poised to thrive with AI breakthroughs and government backing, this stock’s immense potential makes it a must-have for investors now.
Merck MRK announced that the FDA has accepted the biologics license application (BLA) for its investigational prophylactic long-acting monoclonal antibody, clesrovimab (MK-1654), designed to protect infants...
Some stocks sizzle, then fizzle. Others, though, build long-lasting momentum thanks to strong underlying business fundamentals. Three Motley Fool contributors believe they've found stocks in the latter...
Eli Lilly LLY announced results from the phase III EMBER-3 study, which showed that treatment with its orally administered investigational drug imlunestrant significantly reduced the risk of disease progression...
Investors should consider these three penny stocks for their solid upside potential, even after this year's rally.
AstraZeneca AZN and its Japanese partner Daiichi Sankyo announced that the FDA has granted a Breakthrough Therapy designation (BTD) to their antibody-drug conjugate (ADC), datopotamab deruxtecan (Dato-DXd),...
AstraZeneca AZN announced that the FDA has accepted and granted priority review to its supplemental biologics license application (sBLA) seeking expanded use of its blockbuster drug, Imfinzi (durvalumab),...
Whether you're looking for a way to beat the benchmark S&P 500 index or you just want a steady flow of passive income, dividend-paying stocks are a great way to achieve your investment goals.
This week, Eli Lilly’s LLY popular obesity drug, Zepbound showed better weight loss than Novo Nordisk’s Wegovy in a head-to-head study. The FDA granted Breakthrough Therapy designation to Merck’s...
Merck MRK announced that the FDA has granted breakthrough therapy designation (BTD) to sacituzumab tirumotecan (sac-TMT) for the treatment of certain patients with non-small cell lung cancer (NSCLC).The...